Evidence map›Paper›PMID 34642963›Full record

ArticleSeminars in dialysis2022

Development and validation of a risk score to prioritize patients for evaluation of access stenosis.

Brad C Astor, Kim Hirschman, John Kennedy, Stan Frinak, Anatole Besarab

Abstract read
In one paragraph

Article in Seminars in dialysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Quality Metrics in Dialysis: It Takes a Village.Advances in kidney disease and health · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brad C AstorDepartment of Medicine, Division of Nephrology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.ORCID 0000-0002-0876-0069
Kim HirschmanVasc-Alert, LLC, Lafayette, Indiana, USA.
John KennedyVasc-Alert, LLC, Lafayette, Indiana, USA.ORCID 0000-0002-1500-6961
Stan FrinakDepartment of Internal Medicine, Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan, USA.
Anatole BesarabDepartment of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccess flow dysfunction, often associated with stenosis, is a common problem in hemodialysis access and may result in progression to thrombosis. Timely identification of accesses in need of evaluation is critical to preserving a functioning access. We hypothesized that a risk score using measurements obtained from the Vasc-Alert surveillance device could be used to predict subsequent interventions.

methodsMeasurement of five factors over the preceding 28 days from 1.46 million hemodialysis treatments (6163 patients) were used to develop a score associated with interventions over the subsequent 60 days. The score was validated in a separate dataset of 298,620 treatments (2641 patients).

resultsInterventions in arteriovenous fistulae (AVF; n = 4125) were much more common in those with the highest score (36.2%) than in those with the lowest score (11.0). The score also was strongly associated with interventions in patients with an arteriovenous graft (AVG; n = 2,038; 43.2% vs. 21.1%). There was excellent agreement in the Validation datasets for AVF (OR = 2.67 comparing the highest to lowest score) and good agreement for AVG (OR = 1.92).

conclusionsThis simple risk score based on surveillance data may be useful for prioritizing patients for physical examination and potentially early referral for intervention.

Indexed as

Arteriovenous Shunt, SurgicalConstriction, PathologicGraft Occlusion, VascularHumansRenal DialysisRisk FactorsTreatment OutcomeVascular Patency

Identifiers

PMID34642963
PMCPMC9292738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.